# Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/RYTM
## Company Profile
- Ticker: RYTM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 112.845 USD
- Market cap: 5785867966.9 USD
- Last updated: 2026-08-11
## Business Overview
### Rare Neuroendocrine Diseases
Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine disorders characterized by pathological hunger and severe obesity. Its programs focus on restoring melanocortin-4 receptor pathway signaling in genetically or structurally defined patient populations.
### IMCIVREE Franchise
IMCIVREE, or setmelanotide, is an MC4R agonist approved for several forms of syndromic, monogenic and acquired hypothalamic obesity. The product is commercialized in the United States and selected international markets and is being expanded through additional regulatory submissions and clinical studies.
### Acquired Hypothalamic Obesity
Following FDA and European authorization, Rhythm launched IMCIVREE in the United States for acquired hypothalamic obesity and is preparing country-level European access. A Japanese application is also under regulatory review based on the TRANSCEND program.
### Lifecycle and Next-Generation Programs
The company continues to study setmelanotide in congenital hypothalamic obesity. RM-718 is a next-generation MC4R-pathway candidate in Phase 1/2 development for Prader-Willi syndrome.
## Why The Stock Is Moving

As of Aug 11, 2026, RYTM closed down 2.28% at $112.84. No new same-company headline was identified in the current news window.

## Future Catalysts

- Japanese PMDA decision on IMCIVREE for acquired hypothalamic obesity expected in the second half of 2026, with a potential launch by year-end.
- Completion of enrollment in the setmelanotide congenital hypothalamic obesity substudy expected in the second half of 2026.
- Completion of enrollment in Part D of the RM-718 Phase 1/2 trial in Prader-Willi syndrome expected in the second half of 2026.
- European country launches for acquired hypothalamic obesity anticipated in 2027.

## Recent News
- 2026-08-04 20:01 EST — [Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-26fad73b) — Source: Rhythm Pharmaceuticals
- 2026-08-04 11:01 EST — [Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-reports-second-quarter-2026-financial-results-and-busines-bf05205a) — Source: Rhythm Pharmaceuticals
- 2026-08-04 10:55 EST — [Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity](https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-preliminary-data-from-phase-2-trial-that-showed-a30ab64d) — Source: Rhythm Pharmaceuticals
- 2026-07-21 12:00 EST — [Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026](https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-tuesda-7e7002e7) — Source: Rhythm Pharmaceuticals
- 2026-07-08 21:07 EST — [Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity](https://biopharmsignal.com/news/RYTM/rhythm-pharmaceuticals-announces-the-new-england-journal-of-medicine-publication-d9ff91a2) — Source: Rhythm Pharmaceuticals